Key Takeaways VCYT's Afirma posted 13% volume growth in Q3 2025, driven by new account wins and higher use per account. Decipher franchise ran 26,700 tests in Q3 2025, with expansion into bladder cancer and Medicare coverage. Veracyte ended Q3 2025 with $366M in cash and no debt, though macro pressures pushed costs higher. Veracyte (VCYT) is making solid progress in its Afirma business line. The company’s Decipher franchise continues to be a strong tailwind, with remarkable test volume growth. Sound financi ...